ArticleBMJ open2018
Exploiting science? A systematic analysis of complementary and alternative medicine clinic websites' marketing of stem cell therapies.
Article in BMJ open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- The Availability and Pricing of Orthobiologic Knee Injections in the Chicago Metropolitan Area: A Market Assessment Study.Orthopaedic journal of sports medicine · 2025Article
- Unapproved and unproven cancer treatments in patients admitted to palliative care units.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- US state laws on medical freedom and investigational stem cell procedures: a call to focus on state-based legislation.Cytotherapy · 2024Article
- Alternative cancer clinics' use of Google listings and reviews to mislead potential patients.BJC reports · 2024Article
- Stromal vascular fraction in the treatment of myositis.Cell death discovery · 2023Review
- Advertising Alternative Cancer Treatments and Approaches on Meta Social Media Platforms: Content Analysis.JMIR infodemiology · 2023Article
- Difficulties in ensuring review quality performed by committees under the Act on the Safety of Regenerative Medicine in Japan.Stem cell reports · 2023Review
- Clinical use of autologous cell-based therapies in an evolving regulatory landscape: A survey of patient experiences and perceptions.F1000Research · 2023Article
- Regenerative Medicine: Case Study for Understanding and Anticipating Emerging Science and Technology.NAM perspectives · 2023Review
- Tracking discussions of complementary, alternative, and integrative medicine in the context of the COVID-19 pandemic: a month-by-month sentiment analysis of Twitter data.BMC complementary medicine and therapies · 2022Article
- Role of Physicians in Guiding Patients Away From Unproven Stem Cell Interventions.Texas Heart Institute journal · 2022Article
- Online marketing practices of regenerative medicine clinics in US-Mexico border region: a web surveillance study.Stem cell research & therapy · 2021Article
- Neuroenhancement for sale: assessing the website claims of neurofeedback providers in the United States.Journal of cognitive enhancement : towards the integration of theory and practice · 2020Article
- COVID-19 and 'immune boosting' on the internet: a content analysis of Google search results.BMJ open · 2020Article
- Regenerative medicine therapies: lessons from the kidney.Current opinion in physiology · 2020Review
- Challenging misinformation and engaging patients: characterizing a regenerative medicine consult service.Regenerative medicine · 2020Article
- Rogue stem cell clinics.The bone & joint journal · 2020Article
- Marketing Experimental Stem Cell Therapies in the UK: Biomedical Lifestyle Products and the Promise of Regenerative Medicine in the Digital Era.Science as culture · 2020Article
- Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action.BMC medical ethics · 2019Article
- On Patient Safety: Regenerative Medicine-The Hype Amplifies Safety Concerns.Clinical orthopaedics and related research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveTo identify the frequency and qualitative characteristics of stem cell-related marketing claims made on websites of clinics featuring common types of complementary and alternative medicine practitioners. The involvement of complementary and alternative medicine practitioners in the marketing of stem cell therapies and stem cell-related interventions is understudied. This research explores the extent to which they are involved and collaborate with medical professionals. This knowledge will help with identifying and evaluating potential policy responses to this growing market.
designSystematic website analysis.
settingGlobal. US and English-language bias due to methodology.
main outcome measuresRepresentations made on clinic websites in relation to practitioner types, stem cell therapies and their targets, stem cell-related interventions. Statements about stem cell therapies relating to evidence of inefficacy, limited evidence of efficacy, general procedural risks, risks specific to the mode of therapy, regulatory status, experimental or unproven nature of therapy. Use of hype language (eg, language that exaggerates potential benefits).
results243 websites offered stem cell therapies. Many websites advertised stem cell transplantation from multiple sources, such as adipose-derived (112), bone marrow-derived (100), blood-derived (28), umbilical cord-derived (26) and others. Plant stem cell-based treatments and products (20) were also advertised. Purposes for and targets of treatment included pain, physical injury, a wide range of diseases and illnesses, cosmetic concerns, non-cosmetic ageing, sexual enhancement and others. Medical doctors (130), chiropractors (53) and naturopaths (44) commonly work in the clinics we found to be offering stem cell therapies. Few clinic websites advertising stem cell therapies included important additional information, including statements about evidence of inefficacy (present on only 12.76% of websites), statements about limited evidence of efficacy (18.93%), statements of general risks (24.69%), statements of risks specific to the mode(s) of therapy (5.76%), statements as to the regulatory status of the therapies (30.86%) and statements that the therapy is experimental or unproven (33.33%). Hype language was noted (31.69%).
conclusionsStem cell therapies and related interventions are marketed for a wide breadth of conditions and are being offered by complementary and alternative practitioners, often in conjunction with medical doctors. Consumer protection and truth-in-advertising regulation could play important roles in addressing misleading marketing practices in this area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.